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ABSTRACT 
Background 
The ALVAC/HIV+ gp120/Alum RV144 vaccine trial conducted in Thailand resulted in 31% vaccine 
efficacy in a low-risk cohort of 16.000 volunteers.  We aimed to mirror these results in an SIVmac251 
model, to explore the effect of the  adjuvant MF59 in a similar vaccine regimen and to investigate 
the immune correlates of protection. Post-hoc analysis of RV144 demonstrated that antibodies 
targeting the V2 region of gp120 correlated with decreased risk of infection. The same response has 
been detected in SIV-infected rhesus macaques that achived substained SIV control after treatment 
with monoclonal antibody anti-α4β7 and an intermittent period of antiretroviral therapy. To date, V2 
antibody response data in HIV infected individual that naturally control HIV progression are lacking. 
We compared the V2 humoral response in a group of chronic HIV infected patients that never 
received ART and compare that to the response in HIV infected patients Long Term Non Progressors 
(LTNPs).  
Methods 
We immunized 54 rhesus macaques with an RV144 like vaccine regimen adjuvanted either in alum 
or MF59. We compared the efficacy of the vaccine to 24 simultaneous controls, as well as 23 his-
torical controls. We challenged all the animals with repeated intra-rectal low doses of SIVmac251. We 
evaluated vaccine efficacy, measured humoral systemic and mucosal humoral responses by multiple 
antibody detection assays (with particular regard to the V2 response), we measured frequency and 
quality of plasma-cell precursors, Plasmablasts and Natural Killer cells by flow-citometry. We 
enrolled 14 HIV italian patients LTNP and 12 pre-ART chronic HIV-infected (CHI) patients and 
studied their systemic response to V2, with both linear and cyclic peptides.  
 
Results 
Our study mirrored the RV144 human trial: the ALVAC-simian immunodeficiency virus (SIV) and 
gp120 alum (ALVAC-SIV + gp120) reduced the risk of SIV mucosal infection. Interestingly the 
ALVAC-SIV + gp120 MF59 vaccine did not, despite the general higher systemic and mucosal 
immunogenicity. Vaccine efficacy was associated with alum-induced envelope Env-dependent 
mucosal NK-cells that produce interleukin 17 (IL-17), as well as with mucosal IgG to the gp120 
variable region 2 (V2). Notably, this latter humoral mucosal response was the only response higher 
in the alum group. MF59 skewed the traffic of PBs from the mucosal to the inflammatory sites. We 
observed similar differences, consistent with the macaque results, in α4β7 levels on circulating PBs 
in humans immunized in the RV135 and RV132 trials, which used the RV144 immunogens 
adjuvanted either with alum or MF59, respectively. The systemic antibody V2 response in LTNP was 
higher compared to the V2 response in pre-ART CHI patients.  
 
Conclusions 
Our data confirm the protection achieved in human by the immunization with a prime/boost 
approach with an ALVAC-HIV + gp120-Alum vaccine in a SIVmac251 model. We found novel immune 
features (NK-cells and PBs) that might represent immune correlated of protection. Furthermore, we 
confirmed in our model similar responses showed in humans vaccinated with the RV144 regimen. 
As already described in vaccinated humans, we now demonstrate the importance of the antibodies 
to V2 in prevention from SIV mucosal acquisition.  The importance of antibody to V2 region of 
SIV/HIV has been recently corroborated by a rhesus macaque study in which substained virologic 
control was achived after ART suspension. We remarkably found in a group of italian LTNPs an 
higher antibody response to the linear and cyclic form of the V2 region of gp120 compared to a 
group of pre-ART CHI patients. Understanding the mechanism in which these antibody might 
contribute to mediate protection from HIV/SIV acqusition and HIV/SIV control will require further 
studies 
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HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
Historical remarks 
Acquired immune deficiency syndrome was recognized for the first time in the U.S. in 
1981 when the Centers for Disease Control and Prevention (C.D.C.) reported an 
unexplained increased number of cases of Pneumocystis jiroveci (known as P. carinii) 
pneumonia and of Kaposi’s sarcoma in previously healthy homosexual men in Los Angeles 
and in New York [1-4]. Initially, as it was certified that in all these patients a severe 
impairment of their immune system occurred, the disease was called Gay- Related 
Immunodeficiency (GRID). However, within a few months the same disorder was found in 
haemophilics [5] and in recipients of blood transfusion [6] , and later in both male and female 
injection drug users [7]. As the epidemiologic pattern unfolded and the number of cases 
increasingly rose according to a contagious disease fashion, it was evident that it was a 
previously unknown infectious disease, which was not affecting young homosexual men 
only, but could be transmitted to anyone both through sexual activity and blood contact. In 
1982 it was proposed by C.D.C. to name the disease according to the profound alteration of 
the immune response it was strictly associated with: the Acquired Immune Deficiency 
Syndrome (AIDS). AIDS, in fact, included all kinds of opportunistic infections and all forms 
of rare tumors that were frequently found in those patients.  
In 1983, two separate research groups led by Luc Montagnier and Robert Gallo 
independently declared that a novel retrovirus may have been infecting AIDS patients. At 
the Pasteur Institute, in Paris, Montagnier's group observed by electromicroscopy a virus 
from a patient presenting with swelling of the lymph nodes of the neck and physical 
weakness, two typical symptoms of AIDS, and accordingly named the virus 
Lymphadenopathy-Associated Virus (LAV) [8]. On the other hand, Gallo, who was leading 
a virology laboratory at the National Cancer Institute, in Bethesda, claimed that his group 
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had isolated a virus from an AIDS patient. This virus was strikingly similar to other 
retroviruses, namely Human T Lymphotropic Viruses (HTLVs), and called the newly isolated 
virus HTLV-III [9]. However, by March 1985 it became clear that LAV and HTLVIII were the 
same retrovirus and that it was, in turn, the etiologic agent of AIDS. One year later, the 
International Committee on Taxonomy on Viruses ruled that Human Immunodeficiency Virus 
(HIV) was to be the new name from then on. 
HIV structure 
Two major types of HIV have been characterized. HIV type 1 (HIV-1) is the virus that 
was first isolated as LAV in 1983, and the most common cause of HIV disease throughout 
the world. It is closely related to SIVcpz, a specific strain of Simian Immunodeficiency Virus 
virus that infects Pan troglodytes troglodytes species of chimpanzees, which have been 
thought to be the wild source of human infection [10-13]. On the other hand, HIV type 2 
(HIV-2) is confined to some West African regions, probably due to the fact that it is less 
virulent and less infective than HIV-1, and is more strictly related to the African sooty 
mangabeys strains of SIV (known as SIVsmm) [14, 15] . 
The Human Immunodeficiency Virus is roughly spherical, with a diameter of 120 nm. Its 
envelope partially derives from the host cell plasma membrane following the budding 
process, and is studded with 10-100 spikes that protrude through the surface of the virion 
[16]. Each of these spikes comprises a trimer of gp120 (i.e., glycoprotein 120), a heavily 
glycosylated protein which enables the virus to attach the target cell, and gp41, a 
transmembrane protein which plays a critical role in the fusion of the virion with the target 
cell. Both of them are coded by HIV env gene and represent important targets for drug 
treatment and vaccines against HIV. The inner layer of the envelope presents p17 MA (i.e., 
matrix antigen), a viral gag gene product. The core of the virion is covered with p24 CA (i.e., 
capsid antigen), another gag gene product that gives it its cone-like shape. Within the core, 
there are two copies of single-stranded viral genomic RNA and viral proteins that either are 
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required for the assembly of the virion (p7 nucleocapsid protein, NC) or are necessary to its 
replication process (such as reverse transcriptase and integrase) [17]. Similarly to any other 
retrovirus, the HIV genome comprises structural genes, encoding for major proteins and 
essential enzymes, and non-structural genes, encoding for proteins involved in regulation of 
gene expression or modulations of the host cell interactions in order to augment viral 
replication. 
 
The structural genes are gag, pol, and env, sometimes referred to as 5’ gag-pol-env 3’, 
according to their position within the viral genome. Gag (i.e., group-specific-antigen) gene 
encodes for the precursor polyprotein, processed by viral protease into a number of 
structural proteins: 
 
- MA p17 (matrix antigen), which forms the inner layer of the lipid-containing envelope; 
- CA p24 (capsid antigen), which constitutes the skeleton of the viral core; 
- NC p7 (nucleocapsid), which binds to the RNA genome within the viral core; 
- p6, which interacts the with vpr protein. 
 
Pol (i.e., polymerase) gene encodes for a variety of viral enzymes, including:  
- PR p10 (protease), which is essential for the cleavage of gag precursor polyprotein 
and for the processing of all viral enzymes; 
- RT (reverse transcriptase) and RNAse H, a RNA-dependent DNA polymerase and a 
ribonuclease, respectively, which are required to transcribe double-stranded DNA 
from the RNA genome; 
- IN p32 (integrase), which catalyzes the integration of viral DNA into the host genome. 
Env (i.e., envelope) encodes for gp160, a glycoprotein that is cleaved in the endoplasmic 
reticulum into two smaller glycoproteins [18]:  
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- gp120, which mediates the attachment of the virus to the target cell and elicits a 
specific humoral immune response [19, 20]; 
- gp41, which catalyzes the fusion of the virion to the host cell. 
Furthermore, in HIV genome two essential regulatory elements can be identified. Tat 
(transactivator), a transcriptional activator that binds to the TAR (i.e., tat-responsive 
element) RNA region to initiate transcription and elongation from the LTR promoter  (Long 
Terminal Repeats (LTR) are terminally present on both ends of RNA genome and contain 
sequences involved in several regulatory functions, including the initiation of transcription, 
prevention of premature termination, polyadenylation and integration). Rev (regulator of 
expression of viral proteins), a regulatory factor that binds to the RRE (i.e., rev-responsive 
element) RNA region and inhibits viral RNA splicing, promoting nuclear export of 
incompletely spliced viral mRNAs. Finally, other proteins are encoded by HIV non-structural 
genes. Nef (i.e., negative effector) gene encodes for a phosphoprotein that promotes the 
down-regulation of surface CD4 receptors and MHC-I molecules, blocks cell apoptosis, 
increases viral infectivity and somehow alters the state of cellular activation. Vif (i.e., viral 
infectivity factor) encodes for a phosphoprotein in the absence of which the produced viral 
particles are defective. Vpr (i.e., viral protein R) product is involved in the nuclear import of 
pre-integration complexes, cell growth arrest during G2-phase of the cell cycle and 
transactivation of cellular genes. Vpu (i.e., viral protein U) is a gene expressed by HIV-1 
only, and encodes for a protein involved in the degradation of CD4 in the endoplasmic 
reticulum and in the enhancement of virion release from the plasma membrane. Vpx (i.e., 
viral protein X) product is a protein expressed by HIV-2 genome only, known to be a homolog 
of HIV-1 vpr, but further research is needed to fully understand its role in viral replication. 
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HIV pathogenesis. Long-Term Non-Progressors and Elite Controllers 
 Before the introduction of antiretroviral therapy as a means to reduce AIDS-related 
morbidity and mortality, the course of HIV infection resulted in a typical pattern in most of 
the untreated patients. After HIV transmission and the establishment of infection, referred to 
as primary infection, the patient presents high levels of HIV RNA copies (millions per 
milliliter) in the peripheral blood and an almost simultaneous and abrupt drop of CD4+ T cells 
(Fig. 1). 
 
 
 
 
 
 
 
 
 
 
Fig. 1 | Typical course of an untreated HIV-infected individual (From Fauci AS, Braunwald E, Kasper DL, Hauser 
SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-
Hill Medical Publishing Division. 2011). 
 
About 50% of recently infected patients develop the acute HIV syndrome, a cluster of acute 
mononucleosis-like symptoms, reflecting the wide dissemination of virus and the seeding of 
lymphoid organs. Following a partial rebound of CD4+ T-cell count, a long period of clinical 
latency takes place, during which the patient is relatively asymptomatic. However, the term 
is not to be confused with microbiologic latency, since even in patients where HIV RNA 
levels cannot be detected there is always some degree of ongoing viral replication, resulting 
in fact in a progressive and relentless decrease of CD4+ T lymphocytes. It is estimated that 
an average of ten years are necessary for the CD4+ T count to decrease significantly, so 
  
11 
that the Acquired Immune Deficiency Syndrome (also referred to as AIDS) becomes 
clinically evident, and is primarily characterized by severe opportunistic infections and 
neoplasms. In the absence of therapy, most patients are bound to eventually die mainly as 
a result of the profound impairment of the immune system (Fig. 1). 
Individuals with HIV infection show variable rates of disease progression and viral control. 
Whereas some subgroups of individuals control infection very well and remain asymptomatic 
for several years, others show rapid immunological and clinical progression. A number of 
terms have been used to describe individuals at these extremes of the clinical spectrum, 
including Long-Term Non-Progressors (LTNPs) and Elite Controllers (ECs). Although these 
groups have been the focus of intense study, there is no consistency in how they have been 
defined. A recent work conducted a systematic review of the literature [21]. It described the 
heterogeneity in the definitions used, and identified common definitions that may provide a 
framework for developing consensus definitions LTNPs are defined as subject followed up 
from 1 to 25 years with 10 years being the most common duration of follow-up required. The 
CD4+ cell count for this patients range between 300 and 1000 cells/μl. Only 36% of 159 
unique definitions for LTNPs in the literature include a HIV-RNA threshold. The absence of 
clinical symptoms is a prominent criterion.  
Fifthy unique definitions of ECs are present in the literature.  As expected from the 
terminology, HIV-RNA thresholds appeared in all definitions listed, with thresholds ranging 
from 40 to 500 copies/ml. The most frequent HIV-RNA threshold used was 50 copies/ml. The 
duration of follow-up varies from 6 months to 16 years, from definition to definition.  
The possible explanations that lie underneath this phenomenon have been extensively 
reviewed [22]. Research in the field has undergone considerable development in recent 
years and LTNPs offer a piece of the puzzle in understanding the ways that infected 
individuals can naturally control HIV-1 infection. Their method of control is based on viral, 
genetic and immunological components. With respect to virological features, genomic 
sequencing has shown that some LTNPs are infected with attenuated strains of HIV-1 and 
harbour mutant nef, vpr, vif or rev genes that contain single nuclear polymorphisms, or less 
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frequently, large deletions, in conserved domains. Studies have also shown that some 
LTNPs have unique genetic advantages, including heterozygosity for the CCR5-32 
polymorphism, and have been found excitatory mutations that upregulate the production of 
the chemokines that competitively inhibit HIV-1 binding to CCR5 or CXCR4. Lastly, 
immunological factors are crucial for providing LTNPs with a natural form of control, the most 
important being robust HIV-specific CD4+ and CD8+ T-cell responses that correlate with 
lower viral loads. Many LTNPs carry the HLA class I B57 allele that enhances presentation 
of antigenic peptides on the surface of infected CD4+ cells to cytotoxic CD8+ T cells [23]. 
Notwithstanding the extensive literature produced on the viral, genetic and immunological 
feautures of these patients, the exact mechanisms for LTNP are still under investigation. For 
all these reasons, LTNPs and ECs serve as an ideal model for HIV-1 vaccine development 
due to their natural control of HIV-1 infection.  
 
HIV VACCINES 
Vaccines and adjuvants overview 
A vaccine is a biological preparation that creates immunity against a particular 
pathogen, in the effort of providing effective protection to the host. The term vaccine derives 
from Edward Jenner's 1796 use of cowpox (in Latin variola vaccinia), to inoculate humans, 
thereby establishing protection against smallpox. Current vaccines fall in four major 
categories: attenuated, inactivated, subunit, and toxoid [24] .  Live attenuated vaccines are 
the major class of vaccines, especially for intracellular pathogens. The agents that are 
inoculated replicate throughout the body and result in the development of active infections. 
Suitably attenuated strains require low doses of vaccine and lead to a long-lasting form of 
immunity, which is both antibody-mediated and cytotoxic. Furthermore, they are usually 
administered orally and, thus, tend to induce effective mucosal immunity. On the other hand, 
the stability of the vaccine may be poor and reversion to the virulent phenotype may occur. 
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Since its discovery by Louis Pasteur, attenuation became the main route for the 
development of new vaccines. In its easiest form, attenuation simply required the repeated 
passage of the agent in culture until a strain was obtained that exhibited reduced 
pathogenicity but elicited, nevertheless, good immunity. A historical example of this 
approach is the development of the BCG (i.e., Bacillus Calmette-Guerin) vaccine for 
tuberculosis. Although some of them remain the only choice for prevention of certain 
infectious diseases, inactivated vaccines tend to be less attractive than attenuated ones. 
Indeed, the costs are normally higher, since the agent is not able to replicate throughout the 
body and needs to be administered parentally and in greater amounts. The immune 
response elicited is antibody-mediated, and both cytotoxic and mucosal immunity are not 
significantly induced. Usually, also an adjuvant is needed to prime a better immune 
response, in contrast to attenuated vaccines, for which no adjuvant is required. 
Nevertheless, killed vaccines cannot revert to the virulent phenotype and can rely on a good 
stability of the agent. Inactivation is generally achieved with formaldehyde, ethylenemines 
or β-propionolactone. Subunit vaccines are vaccines developed against individual viral 
or bacterial components that play a crucial role in eliciting protective immunity. Although the 
quest for such vaccines initiated before recombinant DNA technology, current developments 
are underpinned by the ability to clone, sequence and express large quantities of the 
relevant antigens in adequate hosts (typically bacteria or yeasts). Subunit vaccines therefore 
are a product of recombinant DNA technology. The most important subunit vaccine is 
represented by HBV vaccine, which largely contributed to decrease the prevalence of 
hepatitis B infection throughout the Western World in the last thirty years. Finally, vaccines 
based on toxoids can provide protective immunity in diseases that result from the activity of 
specific bacterial exotoxins. They are made from inactivated toxic compounds that maintain 
their immunogenicity. This concept has been thoroughly demonstrated with the successful 
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development of vaccines for diphtheria and tetanus early this century. The early procedure 
of toxin inactivation with formaldehyde is still adequate; alternatively, chemical treatment 
with formalin can be used.  Furthermore, there is a broad spectrum of newly optimized 
vaccines that may be useful in the establishment of protective immune responses towards 
pathogens for which no current vaccine is available, such as HIV. Conjugate vaccines are 
created by covalently attaching a poorly immunogenic (usually polysaccharide) antigen to a 
carrier protein (preferably from the same microorganism) or a toxoid, thereby enhancing its 
ability to induce an effective and long-lasting immune response. This technique is used, for 
instance, for the development of Haemophilus influenzae type B vaccine. Virus-like particle-
based vaccines can be obtained through the separate introduction of one or more genes 
that encode for structural proteins and one or more genes that encode for immunogen 
proteins into a vector, which allows their constant expression within infected cells. Viral 
proteins, then, self-assembly spontaneously and bud from the infected cells, giving rise to 
particles that share the backbone structure with wild-type virus, but are not able to actively 
replicate. A considerable number of viruses that are not able to replicate or are not 
pathogenic, namely viral vectors, are currently available to provide the backbone for the 
cloning of genes belonging to micro-organisms that cannot be attenuated properly. Main 
vectors for this purpose are Poxviruses, Alphaviruses, Adenoviruses and Vescicular 
Stomatitis Viruses. In recent years, also DNA vaccination has been established as a novel 
technique to deliver bacterial or viral antigens and prime a protective immune response. The 
gene of interest is inserted into a plasmidic vector, which allows protein expression within 
eukaryotic cells. Naked DNA is then injected intramuscularly or intradermically and engulfed 
by cells, thereby paving the way to the synthesis of an antigen protein and the subsequent 
induction of cellular-mediated immune responses [25].  
An adjuvant is an immunological agent that enhances the immune response to an antigen. 
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Adjuvants are inorganic or organic chemicals, macromolecules or entire cells obtained from 
certain killed bacteria, which may be included in a vaccine to strengthen the recipient's 
immune response. Adjuvants have been used in human vaccines for almost a century, yet 
very few adjuvants are licensed for human use. This has been due, in part, to a lack of 
understanding of their mechanism of action. However, recent insights into the innate 
immune system and its importance in initiating the adaptive immune response have sparked 
the rational design and development of the next generation of adjuvants. Several studies 
have validated one class of pattern recognition receptors (PRRs), namely Toll-Like 
Receptors (TLRs), as vaccine adjuvant targets. Various TLR agonists have been tested in 
humans and the TLR4 agonist monophosphoryl-lipid A (MPL) has been recently licensed in 
Europe and the USA for a vaccine that prevents human papilloma virus (HPV) 
infection[26]. The two important subsets of adjuvants are: inorganic adjuvants (such as 
aluminum salts) and organic adjuvants (such as oil-based adjuvants). 
Aluminum salts (alum) have been in wide use with human vaccines for almost a 
century. This class of adjuvants, which includes aluminum phosphate, aluminum hydroxide, 
and aluminum hydroxyphosphate, is a component of various viral and bacterial vaccines 
such as diphtheria, tetanus, pertussis, hepatitis A and B, rabies, anthrax, and has also been 
used in the RV-144 trial that first verified the partial efficacy of a vaccine regimen against 
HIV infection in Thailand. Alum formulations are particulate in nature, to which the vaccine 
antigens are adsorbed, albeit with distinct characteristics among the different forms of alum 
salts. The initial assumption that alum creates a depot in situ, thereby allowing slow release 
of antigen over time and prolonged exposure to the immune system[27].  Particulate vaccine 
formulations generally are more readily internalized by antigen-presenting cells (APCs) than 
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are soluble antigens and the same is true for alum-adsorbed antigens. The mechanism by 
which antigen uptake is facilitated is not yet clear. Crystalline alum, however, was shown to 
bind lipids on the surface of APCs and trigger a cellular activation cascade leading to 
initiation of an immune response, but without internalized itself by the cells[28], suggesting 
an indirect role in delivering antigen into the antigen-processing pathway. These results are 
in contrast with a previous study using confocal microscopy showing that alum was 
internalized by APCs.159 However, injection of vaccines containing alum elicits profound 
broad local effects on the immune system. Within a few hours after injection, pro-
inflammatory cytokines are released and there is an influx of inflammatory monocytes 
followed by dendritic cells (DCs), natural killer (NK) cells, neutrophils, and eosinophils by 24 
h [29, 30]. During this time, a constellation of cytokines and chemokines are secreted and 
they may facilitate the recruitment and activation of APCs at the site of injection. These 
APCs may then internalize vaccine antigens and migrate to the draining lymph node to prime 
lymphocytes [31].  The immunostimulatory effects of alum are broad, rapid, and seem to 
involve multiple pathways, both direct and indirect. It provokes a strong TH2 response, but 
is rather ineffective against pathogens that require TH1-cell-mediated immunity and  
determines APC recruitment. However, more investigation will be required to fully elucidate 
these mechanisms. 
Oil-in-water emulsions are licensed for use only in human influenza vaccines. 
These include MF59, which was originally licensed for influenza vaccines for the elderly and 
is now being tested  in the RV-144 follow-up trial in South Africa instead of alum (HVTN 100 
and HVTN 702), and AS03, which was recently approved for pandemic influenza 
vaccines. MF59 consists of uniform particles (∼160 nm in size) generated by microfluidics 
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technology and its main constituents are the naturally occurring oil squalene and two non-
ionic surfactants (Tween 80 and Span 85) [26].  Differently from alum, recent evidence have 
shown that MF59 is quickly drained from the injection site [32]. In addition, unlike alum, the 
adjuvant effects of MF59 can be maintained even when the antigen alone is administered 
up to 24 h after injection of MF59 at the same site [32], suggesting that MF59 creates a sort 
of immuno-competent environment within the muscle that could facilitate the development 
of antigen-specific immune responses.  Studies conducted on cells in vitro demonstrated 
that MF59 increased phagocytosis and pinocytosis, and promoted antigen uptake by APCs 
[33]. In that study, MF59 stimulated monocytes, macrophages, and granulocytes to produce 
the chemokines CCL2, CXCL8, CCL3, and CCL4. Stimulated monocytes underwent 
phenotypic changes in accordance with their differentiation toward DCs. These data 
suggested that MF59 does not directly target DCs to internalize antigen, but may act 
upstream by inducing recruitment of DC precursors and their subsequent differentiation [33]. 
Moreover, MF59 significantly increased the number of antigen-loaded APCs in draining 
lymph nodes compared to alum or non-adjuvanted vaccine [34], suggesting a potential role 
in immune-cell presentation. Finally, unlike alum, it elicits both TH1 and TH2 potent immune 
responses, and seems to upregulate interferon-related genes and to play an active role in 
prompting local inflammatory responses [35]. Nevertheless, as is the case for alum, further 
studies are required to better understand the mode of action of MF59. 
 
Brief HIV vaccines history: from Zagury to the RV144 trial 
In April 1984, U.S. Health and Human Services Secretary Margaret Heckler stated 
that  an HIV-vaccine would have been ready for testing in humans in about two years.  From 
that moment more than thirty years have passed, 35 million people are living with HIV and 
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25 million individual died of it. In 2013 more than 2 million new HIV-1 infections have been 
counted globally [36]. The introduction of the highly active antiretroviral therapy, the most 
recent advances in the prophylactic approaches with the introduction of 
tenofovir/emtricitabine administrated to reduce the risk of HIV sexual transmission [37] 
decreased but did not eliminated the HIV-1 pandemic. 90% of the infected population live in 
underdeveloped area of the words where these tools are not available [36]. The 
development of a safe and effective prophylactic HIV-1 vaccine would represent the best 
solution to control the AIDS pandemic. 3 years after the discovery of HIV, the French 
researcher Daniel Zagury tested the first vaccine candidate without any regulatory approval 
and without adequate preclinical testing. He inoculated himself with a vaccine candidate 
containing a genetically engineered version of an HIV protein inside a viral vector based on 
the vaccinia virus (the same virus used in the smallpox vaccine). Zagury also vaccinates 
nine HIV-uninfected children from Zaire (now the Democratic Republic of the Congo), 
making this the first unofficial preventive AIDS vaccine trial [38].  More than 250 clinical trials 
had been conducted, most of them ended in a phase I or II [39]. For the majority of licensed 
vaccines, neutralizing antibodies have provided the best correlate of vaccine efficacy. 
Therefore, in the first 10 years of research on HIV-1 vaccine, scientists tried to use the 
monomeric env gp120 protein to induce env specific humoral immune response. In 1998 
the first efficacy trial of an AIDS vaccine candidate started. VaxGen launched a Phase III 
efficacy trial: AIDSVAX. The trial enrolled 5,400 volunteers, mostly men who have sex with 
men (MSM), in United States, Canada, Netherlands, and Puerto Rico. A year later, another 
arm of the trial began in Thailand, involving nearly 2,500 injection drug users. In both trials 
was administered the HIV gp120 protein and both trials failed to protect from HIV-1 infection 
regardless the induction of  HIV-1 env gp120 specific response. In previous phase I and II 
clinical trials the same immunogens failed to induce broadly neutralizing antibodies (bNabs). 
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All these observations made clear the fact that type-specific antibody response alone was 
not providing protection against HIV-1 infection. In 1992 researchers reported that rhesus 
macaques vaccinated with a live, attenuated simian immunodeficiency virus (SIV) were 
protected against infection, raising hopes that this might be a feasible approach to HIV 
vaccine development. In 1994 early studies in monkeys opened the hypothesis that the 
protection could come from cellular immune response [40]. In this analysis animals with a 
lower viral set point had a specific T lymphocyte response after homologous SIV challenges. 
The negative results coming from the specific env antibody responses in humans together 
with the observations made in rhesus macaques vaccine models lead the way to start in 
2004 the most important phase IIb vaccine trial focused on t cell immunity: the HIV Vaccine 
Trials Network (HVTN) 502 also known as STEP trial. This vaccine was formulated as a 
trivalent mixture of rAd5 vector expressing HIV-1 clade B Gag, Pol and Nef.  The vaccine 
was tested in North and South America, the Caribbean islands, and Australia in 3,000 
volunteers with the aim to either prevent HIV infection or in reduce viral load among 
vaccinated that would have acquired the virus [41]. In 2007 Vaccinations in the STEP trial 
were discontinued after a data safety monitoring board determines that the vaccine was not 
effective. Subsequent data shows that Ad5 may have increased the risk of HIV acquisition 
among a subset of vaccinated [41]. In 2009 a second Ad5 phase IIb exploratory clinical trial 
started. Based on what was known about the Step study findings, there were no signs of 
increased susceptibility to HIV infection among male vaccine recipients who were 
circumcised and lacked antibody responses to Ad5 at enrollment. That is why the HVTN 505 
study was designed to include only those male volunteers with these characteristics. HVTN 
505 evaluated two different vaccines in a prime-boost strategy.  The HVTN 505 vaccine 
regimen consisted of a recombinant DNA-based vaccine (the prime vaccine). The DNA 
prime vaccine (called VRC-HIVDNA016-00-VP) contained genetic material expressing 
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antigens representing Gag, Pol, Nef, Env (clade B). Following completion of the series of 
three immunizations with the prime, vaccine recipients received a single immunization in 
week 24 with a recombinant vaccine (the boosting vaccine) based on a weakened 
adenovirus type 5 (Ad5) to carry the genetic material expressing a matching set of HIV 
antigens to stimulate the immune system. The HVTN 505 study team enrolled 2,504 HIV-
negative MSMs and transgenders. The volunteers were from 18 to 50 years old and lived in 
the United States. During its scheduled interim review, the HVTN 505 DSMB found that the 
investigational vaccine regimen neither prevented HIV infection nor reduced viral load 
among vaccine recipients who later became infected with the virus. In April 2013, the primary 
analysis looked at volunteers who were diagnosed with HIV infection after having been in 
the study a minimum of 28 weeks. In this analysis, 27 HIV infections occurred among the 
vaccine recipients, and 21 HIV infections occurred among the placebo vaccine recipients. 
Based on these findings, the researcheres recommended that to suspend the injections of 
the investigational vaccine. The National Insitute of Allergy and Infectious Diseases (NIAID) 
of the National Institutes of Health, partner of the study, instructed all HVTN 505 study sites 
to immediately cease administering injections. 
The surprising results of the RV-144 trial, an efficacy trial that was started in Thailand in 
2003 with funding from NIAID and the US Army were published at the end of 2009. The trial, 
conducted by the Thailand Ministry of Public Health, tested a combination of two vaccine 
candidates (Sanofi Pasteur’s recombinant canarypox vector vaccine candidate ALVAC-HIV 
vCP1521 and VaxGen’s AIDSVAX B/E) in 16,402 healthy men and women between the 
ages of 18 and 30, primarily at heterosexual risk for HIV infection. Four priming injections of 
a ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 
subunit vaccine (AIDSVAX B/E). In the modified intention-to-treat analysis the vaccine 
efficacy was 31.2%.  Vaccination did not affect the degree of viremia or the CD4+ T-cell 
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count in subjects in whom HIV-1 infection was subsequently diagnosed [42]. The immune 
correlates of protection of this trial indicated that specific antibodies responses against V1V2 
region of Env may have contributed to the protection against HIV-1 infection, whereas high 
levels of Env-specific IgA antibodies may have increased the risk of HIV-1 acquisition. This 
analysis did not find neutralization antibody as correlate but remarkably it seemed that the 
humoral response was effective through mediating other functions as antibody-dependent 
cell-mediated cytotoxicity (ADCC) [43].  Rolland et al. confirmed in an association between 
high V1/V2-binding antibodies and a reduced risk of HIV-1 acquisition providing evidences 
that vaccine-induced V2 responses plausibly had a role in the partial protection conferred 
by the RV144 regimen [44]. The V2 region is a highly variable region of HIV [45] and an 
immunization directed toward that specific region of the gp120  could  not be effective when 
used with clades that do not share the same V2 region structure.   
The development of an AIDS vaccine is affected by the range of virus subtypes as well as 
by the wide variety of human populations that differ in their genetic make-up and their routes 
of exposure to HIV. In particular, the occurrence of superinfection indicates that an immune 
response triggered by a vaccine to prevent infection by one clade of HIV may not protect 
against all other strains. The increasing variety of sub-types found within countries suggests 
that the effectiveness of a vaccine is likely to vary between populations, unless an innovative 
method is developed which guards against many virus strains [46]. Inevitably, different types 
of candidate vaccines will have to be tested against various viral strains in multiple vaccine 
trials, conducted in both developed and developing countries. However, in January 2015 a 
phase I/II Vaccine Immunogenicity Trial, HVTN 100 has started in South Africa.  The vaccine 
regimen used in this study it is similar to the one used in the RV144. Nevertheless two major 
changes that could affect the outcome have been applied: the products that have been used 
are matching the circulating HIV-1 subtypes C and the adjuvant used to conjugate the gp120 
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clade C protein it is an oil in water emulsion, MF59. HVTN has been completed in October 
2016. In order to start an Efficacy phase III trial on human based on the immunogens of the 
HVTN 100 the following four “go” criteria were evaluated:  
1. Presence of IgG binding antibodies to at least 2 of the 3 gp120 vaccine antigens 
administrated; 
2. a non-inferior IgG binding antibody magnitute to gp120 vaccine antigens compared to the 
RV144 trial;  
3. a non-inferior response rate of Env specific CD4+ T cells expressing IL-2 or IFN-gamma 
or CD40L compared to RV144; 
4. Prevalence of IgG binding antibodies to at least 1 clade C V1V2 Env region in more then 
56% of the vaccinated. All the criteria were met and the beginning of the Efficacy Phase III 
study (HVTN 702) was approved.  
The RV-144 Trial 
There have only ever been four large phase III efficacy trials of HIV vaccines in 
humans. The first two were different versions of a vaccine called AIDSVAX; we learnt in 
2003 that neither version prevented infection. The third was the STEP trial, which closed in 
September 2007. This vaccine, which had looked promising in animal studies, proved not 
only to have no effect in humans but actually to increase the likelihood of infection in a subset 
of participants. However, in October 2009, the RV144 trial proved to be modestly, and 
unexpectedly, efficacious, reducing HIV infections in recipients by 31%. The study was the 
result of a collaboration between U.S. and Thai governments [42]. It was a community-
based, randomized, multicenter, double blind, placebo-controlled trial which involved 16,402 
men and women between the ages of 18 and 30 in Rayong and Chon Buri provinces. It is 
currently referred to as RV-144 trial, or Thai trial. The vaccine strategy consisted of a prime-
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boost approach. Four doses of ALVAC-HIV from Sanofi Pasteur (Swiftwater, PA, USA) were 
administered. The last two administration of ALVAC were coupled with AIDSVAX from 
VaxGene (San Francisco, CA, USA) [47]. ALVAC-HIV is a recombinant canarypox vector 
(vCP1521) where clade B-derived gag and protease and clade E-derived env genes were 
inserted inside the DNA genome, thus determining the formation of virus-like particles that 
bud from the cell membrane and elicit a T cell-mediated immune response. AIDSVAX B/E 
is a bivalent subunit vaccine, composed of a mixture of two highly purified glycoproteins 
produced by recombinant DNA in Chinese hamster ovary cells from subtype B (MN) and E 
(A244). The gp120 proteins were covalently bound to a 27-amino acid sequence found in 
the gD protein of herpes simplex virus type 1 (HSV-1), which was then cleaved during the 
purification procedure.  The prime (ALVAC-HIV) was administered at baseline (day 0), 4 
weeks, 12 weeks, and 24 weeks. Boosting with AIDSVAX B/E occurred at weeks 12 and 
24. Testing for HIV was performed at day 0, at 24 and 26 weeks, and every six-months 
during the 3-year follow-up period. Similarly, assessment of behavior associated with 
increased risk of infection occurred at baseline, at week 26 and every six months 
thenceforth. Two primary endpoints were established: prevention of HIV infection and effect 
of vaccination on early viral load after HIV acquisition. The former was assessed on the 
basis of repeated positive results on enzyme immunoassay and Western blotting. The latter 
was defined as the mean among three measurements of HIV-1 RNA levels within 6 weeks 
after serodiagnosis.  Despite the enrollment of 16,402 volunteers, 7 of them were found to 
be HIV-positive before the beginning of the study: although they underwent randomization 
and were included in the intention-to-treat (ITT) group, they were not considered in the 
modified ITT group, which was made of 16,395 individuals, 8197 receiving vaccine and 9198 
receiving placebo. Finally, 6176 and 6366 volunteers from each group, respectively, were 
included in the per-protocol analysis group, as the remainders were ruled out due to 
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inappropriate or incomplete administration of vaccine or placebo. Participants were equally 
allocated in each group (vaccine and placebo) according to several baseline characteristics, 
including sex, age, province of provenience, marital status, number of sex partners, risk 
behavior (e.g., needle sharing, no condom use, symptoms of sexually transmitted disease, 
drug injection, commercial sex work). The study demonstrated for the first time the induction 
of protection from HIV-1 infection following vaccine administration: in the modified intention-
to-treat analysis a significant difference was established between the two groups (vaccinees 
and controls) in regard of rate of HIV-1 infection, showing a vaccine efficacy of 31.2% (p = 
0.04)  (Fig. 2).  
 
 
 
 
 
 
Fig. 2 | Kaplan-Meier cumulative rate of infection, according to Modified Intention-to-treat Analysis, showing a 
vaccine efficacy of 31.2% (From Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and 
AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220). 
 
In addition, a consistent, although not significant, trend was confirmed both in the ITT 
analysis and in the per-protocol analysis, where vaccine efficacy was 26.4% (p = 0.08) and 
26.2% (p = 0.16), respectively. However, there was no significant difference in the mean 
viral load among subjects who were found to be HIV-positive in the vaccine group, as 
compared to those in the placebo group. Some questions, of course, remained 
unaddressed, such as the possibility that the vaccine might be more effective in persons at 
lower risk of infection, or that the efficacy in protected individuals might have decreased over 
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time. Furthermore, a broad constellation of immune responses was induced by the prime-
boost approach strategy, including T-cell line adapted neutralizing antibodies, antibody-
dependent cell-mediated cytotoxicity, CD4+ T-cell proliferation and CD8+ T-cell activation. 
However, at the time of the trial it was not known yet whether these responses were related 
to protection. Haynes and colleagues conducted an in-depth study of protection correlates 
with a consortium having broad-based skills in immunologic investigation and performing 
statistical analyses [43]. The consortium conducted a case-control study that focused on the 
relationship of six primary immune-response variables to the risk of HIV-1 infection. The 
findings indicated that binding IgG antibodies to variable regions 1 and 2 (V1-V2) of the HIV-
1 envelope (Env) glycoprotein 120 correlated inversely with the rate of HIV-1 infection. In 
addition, a complex relationship to risk was observed with levels of monomeric plasma IgA 
antibodies, which were not associated with an overall increased risk of infection as 
compared with controls, but which appeared to mitigate the protective effect of IgG 
antibodies to V1-V2. These IgA responses also appeared to modulate, in a similar fashion, 
a variety of possible protective mechanisms associated with other immune responses, such 
as the avidity of IgG antibodies, antibody-dependent cellular cytotoxicity, neutralizing 
antibodies, and CD4+ T-cell responses. The mechanism for the apparent effect of IgAs in 
inhibition of the protective effect observed with anti-V1V2 IgG antibodies against HIV-1 
infection is yet to be determined. Nevertheless, the only samples available for IgA 
measurements were from peripheral blood, so that immune responses in key compartments, 
such as mucosal sites, remain unknown. 
 
ANIMAL MODELS 
Limitations and streghts 
HIV group M is genetically close to the SIVcpz, a particular strain of SIV which infects 
chimpanzees and causes an AIDS-like illness in the wild [10, 13, 48] . Nevertheless, SIV 
infection in chimpanzees cannot be used as a model since chimpanzees are a protected 
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species. An adequate animal model requires the production of all proteins (including 
receptors and enzymes) that the virus would use within the host in order to replicate. 
Therefore, it is evident that CD4 receptors and CCR5 and CXCR4 co-receptors as well as 
some transcription factors and nuclear export factors all need to be expressed by target cells 
[49]. However, several restriction factors (proteins that are upregulated following production 
of type I interferons and innate immunity activation), which inhibit the establishment of HIV 
infection, have been recently identified, thus accounting for the inability of HIV to infect a 
variety of species other than humans [50]. The major restriction factors are tripartite-motif-
containing protein 5 (TRIM5), apolipoprotein B-editing catalytic subunit-like 3 (APOBEC3), 
Tetherin and SAM-domain- and HD-domain-containing protein 1 (SAMDH1).  These 
restrictions factor act a diferent leves but they all result in an aborted infection [51-54].   
Non-human primate models 
SIV is a lentivirus that comprises a number of species-specific strains. For instance, 
SIVcpz typically infects African chimpanzees (Pan troglodytes troglodytes) and is 
phylogenetically related to HIV-1, at least to M group [10, 13]. On the other hand, SIVsmm is 
specific for the African sooty mangabey (Cercocebus atys) and gave rise to HIV-2 in humans 
and SIVmac in macaques, upon cross-species transmission[55]. Indeed, SIVsmm and SIVmac 
sequences show great similarity with HIV genome. SIV does not cause any disease in its 
natural hosts (i.e., Old World monkeys), even if it preserves its infectivity [56]. The only 
exception is represented by SIVcpz, which is associated with an increase in mortality, 
although not to the same levels as HIV in humans or SIV in non-natural hosts [57]. By 
contrast, SIV strains that are able to infect Asian monkeys do cause a disease, named 
SAIDS, which closely resembles AIDS [58]. Some similarities in natural and non-natural 
hosts have been demonstrated, including high viremia (high viral load), short lifespan of 
productively infected cells, significant depletion of mucosal CD4+ T cells during acute 
infection, significant activation of both innate and adaptive immune response, ineffective 
immune control of infection as showing protection from AIDS does not result from an 
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adaptive immune response that allows the suppression of viral replication. However, even 
more differences have been identified, since in natural hosts the following features have 
been shown: high levels of peripheral CD4+ T cells, preservation of mucosal immunity and 
absence of microbial translocation, acute immune activation resolution and absence of 
chronic immune activation, preferential tropism for effector memory T cells (Tem) instead of 
central memory T cells (Tcm), normal lymph node structure and function, rare pattern of 
vertical transmission. Given that Old World monkeys cannot be used as a model for HIV 
infection, non-natural hosts, such as Asian macaques, where SIV infection closely 
resembles HIV-1 in humans, have become the most common animal model for HIV 
research. Indeed, Asian macaques are being extensively used in many studies for the 
development of effective vaccine strategies and microbicides against HIV-1. Three species 
of macaques are currently utilized: the rhesus macaque (Macaca mulatta), the pig-tailed 
macaques (Macaca nemestrina), and the cynomologus macaque (Macaca fascicularis). 
Rhesus macaques are by far the most widely used and the best characterized animal model 
for HIV infection. 
Rhesus macaques 
SIV infection, as previously described, is very similar to HIV-1 as for the impairment 
of the adaptive immunity and depletion of CD4+ T cells, but it differs from HIV insofar as the 
velocity of disease progression [49]. In humans from 8 to 10 years are necessary to the 
infection to progress to AIDS, whereas in rhesus macaques SAIDS manifestations occur 
within 2 years, resulting in an even more convenient model in terms of both practicality and 
costs. In humans, at the time of infection only few variants of the virus are transmitted to the 
host (genetic bottleneck theory), and genetic variability of infective virions in a single 
individual is due to a variety of mechanisms that occur after the establishment of infection. 
In order to recapitulate these findings in rhesus macaques, it has been recently 
demonstrated that intrarectal challenge with low and repeated doses of SIVmac251 similarly 
results in the transmission of few virus variants, as seen in humans, whereas high-dose 
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challenge does not [59]. Before the beginning of every study, it needs to be considered that 
there are at least two restriction factors that might play an important role after the challenge 
with SIVmac. First, some MHC-I molecules are strongly associated with better containment of 
replication: Mamu A*01, Mamu B*08 and Mamu B*17 all correlate with low levels of viral 
load[60]. Secondly, TRIM5-α actually seems not to alter the susceptibility of macaques to 
SIVmac251 infection [61].  Finally, the limitations of this model need to be addressed. SIV 
strains are less sensitive to drugs that are currently being used as standard in antiretroviral 
therapy SIV strains do not tend to bind CXCR4, as opposed to HIV-1, and use some other 
co-receptors, instead, so that testing of entry inhibitors-based therapy might be further 
complicated [62]. Finally, the scientific community is still making a lot of efforts to assess a 
strategy to create chimeric recombinant genomes, namely SHIV (i.e., Simian Human 
Immunodeficiency Virus), which can infect macaques and express env or pol HIV-1 proteins. 
Rhesus macaque model is still the most reliable for HIV research: recently, it was possible 
to mimic the results of Thai trial in Indian rhesus macaques by using similar vaccine 
regimens and challenging with low and repeated doses of SIVmac251 [63]. However, the 
refinement of pre-existing models and perhaps the development of new ones will pave the 
way to more relevant models. 
 
HIV/SIV CONTROL and HIV/SIV PREVENTION. 
Many laboratories in the world have faced the issue of trying to suppress HIV viral 
load in the absence of antiretroviral therapy (ART). The scientific community has reached 
the extraordinarily success in inducing long term HIV-1 remission under ART. Nevertheless, 
replication competent virus is still present in individuals even several years after the initiation 
of ART and effective suppression of viral load.  Discontinuation of therapy results in viral 
rebound even in people that well control after years of it [64]. There are two scientifical 
strategies that address persistence: eradicate the reservoir (classical “cure”) or control viral 
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rebound (sustained virologic remission). Many groups have tried different ways to find a 
cure, without success. They tried to use latency-reversing agents to deplete HIV reservoirs, 
administer immunotoxic therapy directed at reservoir, perform stem cell transplantation and 
gene editing. On the other hand researchers who aimed to a sustained virologic remission 
have as a goal to discontinue ART and reach control of viremia by either inducing a natural 
HIV-specific immunity, administering therapeutic vaccinations or infusing HIV-specific 
antibodies [65]. HIV envelope induces aberrant signal that increase viral replication, 
increases the susceptibility of the cells to be infected by HIV and induces dysfunction in NK 
cells [66-69]. NK cells lack of CD4 or CCR5 receptors. Considered that, the most probable 
way in which HIV-1 envelope can bind those cells is through α4β7 integrine. The primary 
function of α4β7 is to mediate migration and retention of leuckocytes in the gut. Indeed HIV-
1 evelope protein is able to bind to α4β7 and to induce intracellular signals through α4β7 
expressed on CD4  [70]. The three natural ligands of α4β7 are MadCAM, VCAM-1 and 
Fibronectin. These molecules bind to α4β7 through a tripeptide loop with a common central 
aspartic core (respectively LDT, IDS, LDV). Of note, this tripeptide is very conserved 
amongst HIV and SIV sequences.  The central role of α4β7 during HIV acute infection has 
been recently demonstrated by Ansari et al. [71]. They demonstrated that blocking of α4β7 
during acute infection leads to decreased levels of viral loads in plasma and gastrointestinal 
tissues in SIV-infected rhesus macaques. Based on this observations researcher started to 
investigate the hypothesis that a monoclonal antibody directed α4β7 could protect against 
mucosal transmission of SIV. The results of this study were stunning [72]. Targeting α4β7 
integrin reduced mucosal transmission of SIV and protected gut-associated lymphoid tissue 
from infection. In summary, this study showed that the infusion of anti α4β7 antibody in 
SIVmac251-mucosally exposed-monkey could protect from SIV infection and could induce 
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sustained decrease in proviral load in GALT and other peripheral lymphoid tissues following 
termination of anti-α4β7 treatment in infected animals. These results led the researchers to 
perform another study, in an SIV model, in which they tested the effect of the infusion of 
anti-α4β7 antibody in SIV-infected rhesus under ART [73]. Infusing anti α4β7 antibody to 
NHPs together with a 90-day course of ART initiated 5 weeks post-infection with SIVmac239 
induced long term viral load suppression following discontinuation of antiretrovirals. The 
treated animals showed restoration of CD4+ T-cells in gut and blood. Several potential 
correlates were observed in this study including the increase of the frequency of cytokine-
synthesizing NKp44+ cells and the induction of an antibody response toward the gp120 V2 
domain. It is of interest that the SIVmac239 V2 peptide target of the response in this study 
overlaps the site of antibody immune pressure in HIV-1 V2 that correlated with decreased 
transmission risk of infection in the RV144 vaccine efficacy trial. The significance of this 
findings in human are unclear and further studies are necessary.  
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AIM OF THE STUDY 
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Today, more people living with HIV than ever before have access to life- antiretroviral 
therapy, which delay the progression of the disease and reduces the likelihood to transmit 
the virus to others. In addition, others who are at high risk for HIV infection have access to 
the Pre-exposure Prophylaxis, being used to prevent HIV. Yet, unfortunately, approximately 
50,000 Americans and 2 million people worldwide became newly infected with HIV in 2014. 
To control and ultimately end HIV globally, a powerful array of HIV prevention tools widely 
accessible to all who would benefit from them are needed Vaccines historically have been 
the most effective means to prevent and even eradicate infectious diseases. They safely 
and cost-effectively prevent illness, disability, and death. Developing safe, effective, and 
affordable vaccines that can prevent HIV infection in uninfected people is the best hope for 
controlling and ultimately ending the HIV/AIDS pandemic.  
 
As previously described, among human clinical studies, only one, the RV-144 trial, 
completed in Thailand, showed marginal efficacy (31.2%) [42]. A preliminary pilot study 
demonstrated that it is possible to recapitulate the protection seen in the Thai trial in an 
animal model for HIV infection [63]. In this model Indian rhesus macaques were vaccinated 
with ALVAC canarypox vector delivering SIV genes and boosted with SIV gp120 protein. 
Similarly to Thai trial, the adjuvant used was alum. Four weeks after the last vaccination 
animals were challenged with repeated low doses of SIVmac251 intrarectally, resulting in 27.3% 
rate of protection from SIV acquisition.  
 
This study seeks to expand upon those data, in order to define vaccine efficacy and 
immune correlates of protection induced by vaccination in the animal model. As the 
preliminary study, a group of 27 Indian rhesus macaques will be vaccinated with the same 
prime-boost approach (ALVAC/gp120). Furthermore, a second group of animals will be 
recruited. In this group, MF59 will be used instead of alum, aiming at assessing vaccine 
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efficacy in a regimen that differed only in the type of adjuvant. Recent studies demonstrated 
that immune correlates of HIV prevention (induction of antibodies against the V2 of gp120) 
are induced in rhesus macaques that control viral replication in absence of ART [72, 73]. 
Therefore, we will explore and investigate the role of some immune correlates (V2 response) 
of protection in a group of LTNP HIV patients.  
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MATERIALS AND METHODS 
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ANIMAL INFORMATION 
The animals used in this study were colony bread Indian rhesus macaques (Macaca 
mulatta) obtained from Covance Research Products (Alice, TX). They were from 3 to 10 
years old, and their weight before the study was greater than 3 kilograms. The animals were 
housed and maintained in accordance with the standards of the Association for the 
Assessment and Accreditation of Laboratory Animal Care (AAALAC). This study was carried 
out in strict accordance with the recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. The Advanced BioScience 
Laboratories, Inc., Institutional Animal Care and Use Committee approved the protocol. All 
efforts were made to minimize suffering. All macaques were negative for simian retrovirus, 
simian T-cell leukemia virus type 1 and herpes B. 
 
STUDY DESIGN AND VACCINE IMMUNOGENS 
All animals used in this study were colony-bred Rhesus macaques (Macaca mulatta), 
obtained from Covance Research Products (Alice, TX). The animals were housed and 
handled in accordance with the standards of the Association for the Assessment and 
Accreditation of Laboratory Animal Care International. Both care and use of the animals 
were in compliance with all relevant institutional (US National Institutes of Health) guidelines. 
The protocol (AUP 491) was approved by the Advanced BioScience Laboratories's 
Institutional Animal Care and Use Committee. 
A total of 54 juvenile macaques were randomized into two groups of 27 macaques, 
according to their major histocompatibility status, gender and weight (average, 3 kg). 
Statistical analysis suggested an 80% probability of detecting significant vaccine efficacy in 
a range of 30–40% (likelihood ratio test) [74]. Although the investigators were unblinded, the 
animal handlers were blinded to the vaccine groups. All 54 macaques were immunized at 
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weeks 0, 4, 12 and 24 with intramuscular inoculations of 108 plaque-forming units (PFU) of 
ALVAC (vCP2432) expressing SIV genes gag-pro and gp120TM (Sanofi Pasteur). The 
sequence of the SIV genes was obtained from a mucosally transmitted founder variant of 
SIVmac251 designated M766r [75]. The gag-pro gene was codon-optimized and constructed 
using human-codon bias, leaving the stem loop and slippery sequences intact to allow for 
the one frame-shift required for pol translation. The gag-pro encodes the entire gag, followed 
by pol, through the end of the protease. The gp120TM gene was codon-optimized and 
constructed using human-codon bias. The native signal peptide was replaced with a 
synthetic signal based on the human tissue plasminogen activator (tPa) signal peptide 
(MDAMKRGLCCVLLLCGAVFVTTTEA). The SIVM766 gp120 from I20 through R527, and 
the 22-residue gp41 transmembrane (TM) domain from Y695 to L716 follows (numbering is 
based on SIVmac251). Six residues of the HIV-1LAI cytoplasmic tail (N706 to G711) follow the 
TM domain (numbering based on HIV-1HXB2 numbering convention). 
At weeks 12 and 24, 27 animals consisting of 12 females and 15 males, 5 MamuA*01+ and 
4 MamuB*17+ (average weight, 5.4 g), were given a bivalent monomeric-gp120 protein 
boost in the opposite thigh of the vector immunization, containing 200 μg each of the 
mucosally transmitted founder variants, SIVmac251-M766 [75] gp120-gD (referred to in the 
text as gp120) and SIVsmE660 gp120-gD CG7V [76]  (referred to in the text as gp120), both 
formulated in alum. The diluted proteins were mixed 1:1 with Alhydrogel 2% (Invivogen, Cat# 
vac-alu-50) by rocking at room temperature for 10 min. An additional group of 27 animals 
(13 females and 14 males, six MamuA*01+ and four MamuB*17+; average weight, 6.7 g) 
were given only 100 μg (as per Novartis's recommendation) of both gp120-gD proteins in 
MF59. 
This study was planned with the provision of using 24 simultaneous controls that received 
alum (n = 6), MF59 (n = 12) or nothing (n = 6), as well as 23 historical controls that received 
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alum (n = 11)6 or gp96-Ig (n = 12)[77]. All controls were housed in the same facility and were 
challenged by the same operators with the same challenge-virus stock. The control group 
had ten MamuA*01+ and six MamuB*17+ animals and an equivalent number of females and 
males. Animals were not screened for TRIM-5α because we previously demonstrated a lack 
of sensitivity to TRIM-5α restriction of this SIVmac251 stock used at the same dose (120 
TCID50) [61]. 
 
VIRAL CHALLENGE 
Four weeks after the final immunization, all animals were challenged with 120 TCID50 
SIVmac251 via the rectal route. Animals testing negative for SIV RNA in plasma were re-
exposed, and a maximum of ten weekly challenges were used. SIVmac251 acquisition did not 
differ in the simultaneous and historical controls. 
 
CELLS, PLASMA AND MUCOSAL SECRETION ISOLATION 
Plasma has been collected as described: blood was collected in EDTA and centrifuged 
after bleeding at 2000 rpm for 10 minutes. Plasma was aliquoted of 0.5-1 ml vials and stored 
immediately at -80C for long term storage. Peripheral blood, plasma and rectal swabs were 
collected from all animals before vaccination (4 weeks prior to immunization) and after the 
fourth immunization (week 25). For immunized human samples (studies RV135 and RV132) 
blood was collected before the immunization and 2 weeks after last vaccination. Peripheral 
blood mononuclear cells (PBMCs) were collected by using Isopaque-Ficoll technique relying 
on differential density gradients to extract PBMCs from whole blood. Rectal swabs were 
placed in 1 ml of cold elution buffer (1 x protease inhibitor cocktail [Calbiochem], 0.25% 
BSA) after collection, in order to prevent antibody degradation. Antibodies were eluted by 
spinning 2 times at 16,000 x g for 15 to 20 minutes at 4C.  
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MEASUREMENT OF VIRAL RNA, DNA AND CD4+ T CELLS 
SIVmac251 RNA in plasma was quantified by nucleic acid sequence–based amplification, 
as previously described [78]. SIV DNA was quantified in mucosal tissues 3 weeks after 
infection by a real-time qPCR assay with sensitivity up to ten copies × 106 cells, as previously 
described [79]. CD4+ T cell counts were periodically determined from whole blood by flow 
cytometry, as previously described [80]. 
 
IgG- and IgA- BINDING ASSAY 
The SIV Env-specific IgG and IgA antibodies in serum and rectal mucosa were 
determined by a custom SIV bAb multiplex assay (SIV-BAMA), as previously described [44, 
81]. For mucosal samples, specific activity was calculated by the ratio of MFI (linear range 
of standard curve)/μg/ml total macaque IgG, which was measured by macaque IgG or IgA 
ELISA to normalize the data to recovery of antibody. Rectal swab samples in solution were 
spun, filtered and concentrated down to approximately half of the starting volume. The 
samples were examined for blood contamination and measured for semiquantitative 
evaluation of hemoglobin. Purified IgG (DBM5) from a SIV-infected macaque (provided by 
M. Roederer, VRC, NIH) was used as the positive control to calculate SIV antibody 
concentration. Positive controls for each antigen were tracked via a Levy Jennings Plot. 
Specific activity was calculated from the total macaque IgG levels and the SIV-specific 
concentrations. Antibodies against native V1/V2 epitopes were quantitated by binding 
assays against native SIV V1/V2 antigens expressed as gp70-fusion proteins related to the 
CaseA2 antigen used in the RV144 correlate study (provided by A. Pinter). These proteins 
contained the glycosylated, disulfide-bonded V1/V2 regions of SIVmac239, SIVmac251 and 
SIVsmE660 (corresponding to AA 120–204 of HXB2 Env), fused to residue 263 of the SU 
(gp70) protein of Fr-MuLV. 
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REAGENTS AND SURFACE PLASMON RESONANCE 
SIV-V2 peptide was synthesized by JPT Peptide Technologies GmbH, Berlin, Germany. 
The peptide was allowed to fold and cyclize under thermodynamic control at high dilution, 
and the purity was determined to be greater than 90% by high-performance liquid 
chromatography and mass spectrometry. The amino acid sequence of the SIV V2 peptide 
is based on the SIVsmE543-3 V2 domain from GenBank accession number U72748. The 
SIV-V2 peptide sequence contains an N-terminal biotin tag and the sequence is as follows: 
GF SIVsmE543 
CIKNNSCAGLEQEPMIGCKFNMTGLKRDKKIEYNETWYSRDLICEQPANGSESKCY.      
GF SIVmac251 full 
CIAQNNCTGLEQEQMISCKFNMTGLKRDKTKEYNETWYSTDLVCEQGNSTDNESRCY. 
CM5 chips and the Biacore amine coupling kit were purchased from GE Healthcare, 
Piscataway, NJ, USA. Streptavidin was purchased from Invitrogen, Grand Island, NY. 
Affinity purified goat anti-monkey IgG and IgA (gamma-chain- or alpha-chain-specific) 
antibody was purchased from Rockland Immunochemicals, Gilbertsville, PA. 
Surface plasmon resonance (SPR) measurements were conducted with a Biacore T200 
using the CM5 chip, as described previously[63]. Streptavidin was immobilized onto the chip 
using the amine coupling kit, as directed by the immobilization wizard packaged within the 
T200 control software. 6,700 reported response units (RU) of 1 μM streptavidin in 20 mM 
sodium formate, pH 4.2 (10 min contact time, 10 μl/min flow rate) was immobilized. The 
biotinylated peptide was prepared at a concentration of 1 μM in 20 mM TRIS, pH 7.4 and 
allowed to flow (at 10 μl/min) over the streptavidin-coated surface of flow cell 4, until 3,500 
RU of SIV V2 peptide were captured. 
The mucosal swabs were thawed on ice and centrifuged at 16,100 rcf, 4 °C, for 5 min. The 
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supernatant was diluted tenfold in TBS, pH 7.4, and then analyzed on the Biacore. The 
diluted mucosal samples were passed over the chip surface at a flow rate of 30 μl/min for 3 
min, followed by a 5-min dissociation period. A 20 μg/ml solution of affinity-purified, gamma-
chain-specific goat anti-monkey IgG or IgA antibody was passed over the peptide-coated, 
Ig-bound surface for 2 min at a flow rate of 10 μl/min. After a 70-s dissociation period, the 
chip surface was regenerated and data were analyzed, as previously described, using the 
BIAevaluation 4.1 software[63]. The RU for the IgG-specific or IgA-specific values are the 
difference between the average value of a 5-s window taken 60 s after the end of the anti-
IgG or anti-IgA injection and the average value of a 5-s window taken 10 s before the 
beginning of the anti-IgG or anti-IgA injection. The data (RU) will be presented in the results 
chapter as dot plots for individual mucosal samples. 
To determine total IgG antibodies in the mucosal samples, anti-IgG immobilization on a CM5 
chip was performed using 100 nM of unconjugated gamma-chain-specific goat anti-monkey 
IgG (Rockland, Inc., Gilbertsville, PA) in 20 mM sodium acetate, pH 4.2, with a 5-min contact 
time and 10 μl/min flow rate, resulting in the immobilization of 9,100 RU. Centrifuged 
mucosal samples (diluted 1:10) were passed over the chip surface at a flow rate of 30 μl/min 
for 3 min, followed by a 5-min dissociation period. The relative amount of monkey IgG was 
determined using the same secondary injection and analysis strategy described above. 
Chemstrips were used to determine the blood contamination in mucosal samples. 10 μl of 
the mucosal supernatant sample was spotted onto a Chemstrip 5 OB Urine Test Strip 
(Roche, cat. #11893467-160). After 60 s, any change in color was recorded for comparison 
to the manufacturer's color chart. 
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REAGENTS AND SURFACE PLASMON RESONANCE FOR CYCLIC V2 
PEPTIDES BY BIACORE 4000 FOR HUMAN SAMPLES  
Reagents:  
Goat-Anti-human-IgG (gamma chain) Binding Sites (cat# 617-101-012 Lot#: 33560) 
Amine coupling kit (cat#: BR-1000-50, lot#: 2077015, GE Healthcare) 
The CM7-S series chip (cat#: 28-9538-28, lot#: 10239700, GE Healthcare)  
Sodium acetate pH 4.5 (cat#: 28-9538-28, lot#: 20278962011, GE Healthcare) 
Hepes buffer (10 mM Hepes, 150 mM NaCl pH 7.4): lot#: CH#20160321 (self-prepared) 
Streptavidin (Cat#: SNN10001, lot#: 1634103A, Life Tech)  
HIV peptides:  
Peptide synthesis by JPT, Germany, HPLC and LCMS quality control 
1. Cyclic biotin V2.AE.92TH023 (lot#: 16716_1, bath#: 120911A5, JPT) 
CSFNMTTELRDKKQKVHALFYKLDIVPIEDNTSSSEYRLINC 
 2. Cyclic biotin V2.B.CaseA2 (lot#: 16816_1a, bath#: 101011A2, JPT) 
 CSFNITTSIRDKVQKEYALFYKLDIVPIDNPKNSTNYRLISC 
 3. Cyclic biotin V2.B (MN) (lot#: 22038_1, batch#: 011111A2W1013, JPT) 
 CSFNITTSIGDKMQKEYALLYKLDIEPIDNDSTSYRLISC 
  4. Cyclic biotin V2.C.1086 (lot#: 24653_6, bath#: 1012114HS-Ksch2, JPT) 
 CSFKATTELKDKKHKVHALFYKLDVVPLNGNSSSSGEYRLINC 
Sample preparation:  
To deactivate the complements and remove lipid contents, sera (105 µL) were heated at 
56°C for 45 min followed by centrifugation at 16,000 x g at 4°C for 20 min.  The supernatants 
were collected and stored at  -80°C for Biacore assay. 
 
Sample analysis:  
The immunogenicity assessment for cyclic V2 peptides was conducted using Biacore 4000 
system. The immobilizations were completed in 10 mM Hepes and 150 mM NaCl pH 7.4 
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using a standard amine coupling kit. The CM7-S series chip surface was activated with a 
1:1 mixture of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) 
and 0.1 M N-hydroxysuccinimide (NHS) for 600 s. Then 1 µM Streptavidin in 10 mM sodium 
acetate pH 4.5 was immobilized for 720 s (11,400 12,300 RU). The immobilized surface was 
then deactivated by 1.0 M ethanolamine-HCl pH 8.5 for 600 s. Spot 3 in each flow cell was 
left unmodified to serve as a reference. After the surface deactivation, 2.5 µM cyclic 
biotinylated peptide of AE.92TH023. V2 (cbV2_AE): 4,700 - 4,800 RU, B.MN. V2 (cbV2.MN): 
4,000 RU, B.caseA2. V2 (cbV2.BcaseA2): 5,200 – 5,400 RU, C.1086. V2 (cbV2.C): 4,900 
RU was captured. Following the surface preparation, the heat-inactivated plasma was 
diluted (1:40) in 10 mM Hepes, 150 mM NaCl pH7.4. The diluted plasma was injected onto 
the captured surface for 300 s followed by a 30 s dissociation period. The bound antibodies 
were then enhanced by the injection of a secondary antibody, goat anti-human IgG antibody 
(30 µg/ml) for 360 s. To regenerate the bound surface, 175 mM HCl was injected for 60 s. 
Each sample was tested in quadruplicate for each peptide at a rate of 10 Hz and analysis 
temperature at 25∘C. All sample injections were conducted at a flow rate of 10 µl/min. Data 
analysis was performed using Biacore 4000 Evaluation software 4.1 with double 
subtractions for unmodified surface and buffer for blank.  
PHENOTYPIC ANALYSES OF PLASMABLASTS 
The frequency of PBs was measured in the blood of 23 macaques vaccinated with 
ALVAC–SIV + gp120 MF59 and 22 macaques vaccinated with the ALVAC–SIV + gp120 
alum regimen, before vaccination and at 7 d after the last immunization. Not less than 10 
million cells at a time were stained with Ax700 anti-CD3 (SP34-2; cat. #557917, 1:80 
dilution), anti-CD14 (M5E2; cat. #557923, 1:50 dilution), anti-CD16 (3G8; cat. #557920, 1:85 
dilution), anti-CD56 (B159, cat. #557919, 1:50 dilution), PECy7 anti-CD21 (B-ly4; cat. 
#561374, 1:85 dilution), PE anti-Ki67 (B56, cat. #556027, 1:25 dilution), PerCPCy5.5 anti-
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IgM (G20-127; cat. #561285, 1:50 dilution); Qdot605 anti-IgG (G18-145; cat. #562025, 1:50 
dilution) and PECF594 anti-CXCR3 (1C6; cat. #562451, 1:50 dilution) from BD Biosciences; 
PECy5-CD19 (J3-119; cat. #IM2643U, 1:30 dilution, Beckman Coulter); 650-CD20 (2H7; 
cat. #95-0209, 1:50 dilution, eBiosciences); FITC-CD38 (AT-1; cat. #10415, 1:250 dilution, 
StemCell); BV421-CD39 (MOCP-21; cat. #328214, 1:50 dilution, BioLegend); IgA-Texas 
Red (polyclonal; cat. #2050-07, 1:50 dilution, SouthernBiotech) and APC-α4β7 (cat. #11718, 
1:50 dilution, NIH AIDS Reagent Program, Division of AIDS, NIAID). Cells were 
permeabilized with Cytofix/Cytoperm (BD Biosciences). Acquisition was performed on LSRII 
(BD Biosciences), and data were analyzed by FlowJo software (TreeStar). PBs were gated 
as lineage-negative (CD3−CD14−CD16−CD56−) CD20+CD21−Ki67pos/high (CD38pos/high 
CD39+) [82]. Cells in this gate were positive for IgG, IgA and IgM, thus validating this panel 
to detect both PBs and plasma cells in macaques. The frequency of PBs expressing CXCR3 
or α4β7 was calculated. 
 
RV135 AND RV132 STUDY DESIGN AND IMMUNOGENS 
The frequency of PBs expressing CXCR3 or α4β7 was assessed also in PBMCs collected 
at 2 weeks after the final immunization from 17 volunteers vaccinated with ALVAC–HIV + 
gp120 alum (RV135) and 17 vaccinated with ALVAC–HIV+ gp120 MF59 regimen (RV132). 
Both RV135 and RV132 studies had a double-blind placebo-controlled phase 2, and were 
approved by the appropriate Institutional Review Boards, specifically by four ethical-review 
committees in Thailand and the United States ((i) Ministry of Public Health Ethical Review 
Committee of Research in Human Subjects (MoPH EC) —FWA00001953; (ii) Institutional 
Review Board, Royal Thai Army Medical Department (IRBRTA)—FWA00001813; (iii) 
Mahidol University Central Institutional Review Board (MU-CIRB)—FWA 00000926; (iv) 
Office of Research Protections, Human Research Protection Office (ORP HRPO)) and by 
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the National AIDS Commission of Thailand. Volunteers were healthy, HIV-negative Thai 
adults, and written informed consent was obtained. The vaccines used in those trials were 
ALVAC–HIV (vCP1521): Recombinant canary-pox vector expressing gag and protease 
subtype B (LAI) and Env-gp120 CRF01_AE (92TH023) linked to the transmembrane-
anchoring portion of subtype B gp41 (LAI) genes (Sanofi Pasteur), bivalent HIV-1 gp120 
SF2 50 μg (subtype B) and gp120 CM235 100 μg (CRF01_AE) adjuvanted with MF59 
(Novartis) and AIDSVAX B/E: bivalent gp120 MN 300 μg (subtype B) and gp120 A244 300 
μg (CRF01_AE) adjuvanted with alum (Global Solutions for Infectious Diseases, GSID, 
South San Francisco, CA) [83, 84]. 
In the human samples, B cells were defined as CD20+CD19+ CD27+. PBMCs were 
collected from vaccines before and 2 weeks after the last immunization. 
 
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF MUCOSAL NK-CELLS. 
Rectal biopsies were obtained 1 week after the last immunization (week 25). Mononuclear 
cells were isolated from rectal biopsies. For the phenotypic characterization, 3 × 106 cells 
were used, and flow cytometry staining was carried out for cell-surface and intracellular 
molecules using standard protocols. After this, anti-human fluorochrome-conjugated mAbs 
known to cross-react with rhesus macaques were used for the staining: AlexaFluor 700 anti-
CD3 (SP34-2, cat. #557917, 0.2 mg/ml), APCCy7 anti-CD8 (SK1, cat. #561945, 5 μl) 
PerCPCy5.5 anti-CD4 (L200; cat. #552838, 5 μl) from BD Biosciences (San Jose, CA); V450 
anti-TNF-α (Mab11; cat. #502920, 5 μl), NKp44 (P44-8; cat. #325110, 5 μl), PECy5 anti-
CD40L (24-31; cat. #310808, 5 μl) 605NC anti-IL-2, (17H12; cat. #500331, 50 μg/ml), 
605NC anti-CD20 (2H7, cat. #302334, 50 μg/ml) from BioLegend (San Diego, CA); PE-CY7 
anti-IL-17 (eBio64DEC17; cat. #25-7179-42, 0.125 μg), FITC anti-CD107a (eBioH4A3; cat. 
#11-1079-42, 5 μl, 0.5 μg) from eBioscience (San Diego, CA); PE anti-NKG2A (Z199; cat. 
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#PN A60797, 5 μl) from Beckman Coulter (Fullerton, CA). The yellow and aqua LIVE/DEAD 
viability dyes (Invitrogen, cat. #L34959, 1 μl) were used to exclude dead cells. At least 
50,000 CD3− singlet events (were acquired on a LSR II (BD) and analyzed using FlowJo 
Software (TreeStar). Mucosal NK cell were gated on live lymphocytes, which were negative 
for CD20 and CD3 and further classified on the basis of the expression of NKG2A and 
NKp44 surface markers [85, 86]. 
 
HIV PATIENTS  
Patients were selected from our HIV outpatient clinic and underwent informed written 
consent. In order to characterize and study the humoral response to the envelope we 
enrolled patients belonging to two distinct groups: 
1. CHRONIC HIV INFECTION, PRE-ART (CHI). These patients have been 
infected with HIV for at least six months and are naïve for antiretroviral 
therapy.  
2. LONG TERM NON-PROGRESSORS. These patients have been infected 
with HIV for at least eight year, naïve for antiretroviral therapy, not affected 
by CD4 loss and. The CD4+ cell count for this patients has been determined 
over 250 cells/μl at the enrollement. Absence of clinical symptoms.  
All patients shared the same exclusion criteria: 
• Age below 18 years 
• Serology positive for HIV-2 
• Previous administration of experimental vaccines aimed to elicit HIV-specific 
immunization 
Peripheral blood was collected during follow up visits. Thirty milliliters were drawn 
in one single phlebotomy.  
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Ethylenediaminetetraacetic acid–anticoagulated blood that was collected and 
processed by centrifugation to separate plasma. Peripheral blood mononuclear 
cells were harvested by Ficoll hypaque centrifugation, washed, counted and stored 
as cell pellets or cryopreserved in FBS-DMSO freezing medium. All samples were 
stored at -80°C, with the exception of live cells, kept in liquid nitrogen.  
Virological data and history of HIV infection were collected from clinical charts and 
gathered in a dedicated database (Table 1). 
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Table 1 | Epidemiological, clinical, immunological and virological characteristics of patients 
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ELISA FOR LINEAR MN PEPTIDES MAPPING FOR HUMAN PLASMA  
For HIV MN pepscan, we coated 1ug/well peptide in 100ul 50mm sodium bicarbonate 
pH 9.6 overnight at 4 deg c in Nunc MaxiSorp plates, emptied wells and blocked with 
200ul/well SuperBlock Blocking Buffer in PBS (Thermo  Scientific) in PBS for one hr at room 
temperature, added  100ul of 1:50 or 1:10 sample in Sample Diluent (AVIOQ, Inc) per well 
and incubated at 37C for one hour, washed plates 5 times with PBS with .05% tween 20, 
added 100ul per well  peroxidase labeled affinity purified antibody to Human IgG produced 
in goat (KPL) at a dilution of 1:120,000 in Dilsm II and incubated at 37C for one hour, washed 
plate 5 times as before, added 100ul per well  K-Blue Aqueous Substrate (Neogen) and inc 
at rt 30min, stopped reaction with 100ul per well 2N sulfuric acid( Cole-Parmer) and read at 
450nm using Molecular Devices E-max plate reader. 
STATISTICAL ANALYSIS 
The Mann–Whitney–Wilcoxon test was used to compare continuous factors between two 
groups. Correlation analyses were performed using the Spearman rank correlation method 
with exact permutation P values calculated. The number of challenges before viral 
acquisition was assessed using the log–rank test of the discrete–time proportional hazards 
model. The Wilcoxon signed–rank test was applied to changes in PB levels from 
prevaccination to postvaccination. Data statistical analysis was performed using GraphPad 
Prism, a 2D graphing and statistics software published by GraphPad Software. 
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RESULTS 
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VACCINE EFFICACY  
We divided 54 rhesus macaques in two vaccine groups.  The animal were randomized and 
controlled for the major histocompatibility complex (MHC)-I, age, weight and gender. All 
macaques were primed with ALVAC–SIV (week 0 and week 4) and boosted  with ALVAC–
SIV coupled with the gD-g p120 M766 and gD-gp120 CG7V (week 12 and week 24) 
formulated either in alum (group 1 n = 27) or MF-59 ( group 2 n = 27). (Fig. 3). The gp120 
proteins used in the study were different in amino acid sequence in order to mirror what 
have been done in the RV144. This clinical trial, in fact,  used the gp120 clades E and B 
(known also as Circolating Recombinant Form 01_AE) matching the circulating clades in 
Thailand [42]. 
 
 
 
 
 
 
Fig. 3 | Study design. Animals were immunized with ALVAC (vCP2432) expressing SIV genes gag-pro and 
gp120TM, derived from the founder variant of SIVmac251 designated M766r and boosted with the SIVmac251 M766 
gp120-gD (referred to in the text as gp120) and SIVsmE660 gp120-gD CG7V (referred to in the text as gp120) proteins 
formulated in alum (200 mg) or MF59 (100 mg). 
 
The amount of protein used was 200 ug in the alum group and 100 ug in the MF59 group 
(dose sparing ajuvant).  Fourty-seven unvaccinated macaques were used as controls (24 
concurrent and 23 historical) and matched vaccinated animals (weight, gender and MHC-I 
alleles). The study was powered to compare the relative vaccine efficacy in vaccinated 
macaques with placebo controls, but not to compare vaccine efficacy between the two 
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regimens. We challenged animals intrarectally weekly with ten repeated low doses of 
SIVmac251, 4 weeks after the final immunization, at week 28. The time of challenge was 
chosen to model early exposure after vaccination, given the fact that enrolled volunteers in 
Thai Trial might have been exposed to HIV either during the vaccination or immediately after 
the end of the immunization. We observed a reduced risk of SIVmac251 acquisition relative to 
unvaccinated controls only in the group of animals vaccinated with ALVAC–SIV + gp120 
alum (log–rank test; P = 0.020, vaccine efficacy of 44% at each challenge) (Fig. 4a). The 
infection rate in the group immunized with the ALVAC–SIV + gp120 MF59 vaccine strategy 
was not different from the infection rate observed in the placebo control  (log–rank test, P = 
0.562) (Fig. 4b)  We observed no evidence of enhancement or viral suppression in the 
plasma (Fig. 4c,4d) of the vaccinated macaques that became infected in either arm of the 
study. The two vaccine regimens did not prevent the loss of CD4+ T cells in macaques that 
became infected (Fig. 4e). 
 
Fig. 4 | a, b. SIVmac251 acquisition. The number of intra-rectal (IR) exposures before viral acquisition was assessed 
in the (a) alum and (b) MF59 groups, relative to the controls, using the log-rank test of the discrete-time proportional 
hazard model. Study design and vaccine efficacy.  c, d. SIV RNA levels in the plasma. Error bars show logarithmic 
mean ± s.d. of animals vaccinated with alum (c) or MF59 (d), and all historical and concurrent control animals (n = 
47).   e. Percentage of CD4+ T cell changes in the blood over time (weeks) (mean ± s.e.m.). 
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HUMORAL RESPONSES AND THE ROLE OF  gp120-cV2 
In order to scan the humoral response and to understand its role in the reduced risk of 
acquisition, the titers of specific antibodies (IgG and IgA) were investigated in both groups 
of animals. Overall the vaccination with ALVAC–SIV + gp120 MF59 induced higher levels 
of systemic binding antibody to SIV Env proteins than alum, both IgG (Fig. 5a, 5b,5c,5f) and 
IgA (Fig. 5d, 5e). 
 
 
 
Fig. 5 | All vaccinated animals in the alum group are in red (n = 27) and those from the MF59 (n = 27) and 
controlgroup (n = 8) are in blue and black respectively. a. IgG titers in serum against the gp130 of SIVmac251 and b. 
the gp140 SIVsmE660. c. Serum IgG titers to the gp70-V1/V2 scaffold of SIVmac251. d. IgA titers in serum against the 
gp130 of SIVmac251 and e. the gp140 SIVsmE660 f. Serum IgG titers to the gp70-V1/V2 scaffold of SIVsmE660. 
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Similarly the levels of binding antibodies in the rectal mucosa were higher in the MF59 group 
compared to the alum group (Fig. 6a, 6b, 6c, 6d).  
 
 
 
Fig. 6 | Env-specific IgG responses in mucosa. The alum group is in red (n = 27) and the MF59 in blue (n = 27) . a. 
Specific activity of rectal IgG-binding antibodies to the gp130 of SIVmac251 and b. to the gp140 SIVsmE660. c. Specific 
activity of IgG-binding antibodies to the gp70-V1/V2 scaffold of SIVmac251. and d. to the gp70-V1/V2 of SIVsmE660 
 
Notably, although the levels of IgG to cyclic V2 (cV2) were higher in the serum of the MF59 
group than in that of the alum group (Fig. 7a, 7b), cV2 IgG was higher in rectal secretions 
from the alum group than in those from the MF59 group (Fig 7c, 7d), Importantly, among the 
alum-treated macaques, the mucosal cV2 IgG response was associated with a decreased 
risk of SIV acquisition (log–rank test, P = 0.0018) (Fig 7e). By contrast, rectal IgG antibodies 
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to cV2 were correlated with an increased risk of SIVmac251 acquisition in the MF59 group 
(log–rank test, P = 0.0016) (Fig 7f). 
 
 
Fig. 7 | Serum and rectal IgG to cyclic V2 and SIVmac251 acquisition  a. Serum IgG to cV2 of SIVmac251  b.  Serum IgG 
to cV2 of SIVsme543.  c. Rectal IgG to cV2 of SIVmac251 d. Rectal IgG to cV2 of SIVsme543.3  e.  SIVmac251 acquisition in 
vaccinated animals that had post-vaccination rectal IgG response units to cV2 of SIVsmE543 >0 (solid lines) or 0 (dotted 
lines) in the alum group f. SIVmac251 acquisition in vaccinated animals that had post-vaccination rectal IgG response 
units to cV2 of SIVsmE543 >0 (solid lines) or 0 (dotted lines) in the MF59 group 
 
PLASMABLASTS  
The difference in the distribution of the antibody response against cV2 in plasma and 
mucosal sites induced us to study the homing marker receptors on the surfaces of early 
plasma-cells precursors, plasmablasts (PBs). PBs are short-lived, highly proliferating, 
antibody-secreting, plasma-cell precursors, which are found in peripheral blood upon 
antigen exposure and migrate toward tissues according to their homing markers expression 
[87]. The presence of interferon-  (IFN- ), a hallmark of inflamed tissue, increases the 
expression on PBs of the chemokine receptor CXCR3 and of CXCL10 (ligand of CXCR3) 
by cells located in inflammatory sites. On the other hand, the role of surface integrins, such 
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as α4β7, has emerged as crucial to understand PBs migratory patterns to mucosal site and 
the induction of local immunity [88]. The levels of α4β7 and of the chemokine receptor 
CXCR3 were measured before and after immunization on total PB subsets (Fig. 8).  
 
Fig. 8 | Phenotypic characterization of PBs. Plots represent the gating strategy, where gating is represented by 
squares or circles and the arrows represent the parent-to-daughter population flow for each line. 
 
Alum adjuvant did not significantly alter the expression of either molecule (Fig. 9a, 9b), as 
compared to pre-vaccination specimens, whereas MF59 did (Fig. 9a, 9b), resulting in a 
significantly higher level of α4β7+ PBs in the alum group than in the MF59 group (P = 0.20)  
(Fig. 9c). MF59 was also associated with a significant increase (P < 0.001) above the 
baseline in the number of CXCR3+ PBs in macaques (Fig. 9b) resulting in a significantly 
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higher level of CXCR3 expression on PBs in MF59 group than in the alum group (P = 0.007)  
(Fig.9d).  
 
Fig. 9 | Adjuvant associated differences in PBs homing markers in blood. a. Percentage of α4β7+ and b.  CXCR3+ 
PBs in macaques’ blood (MF59 n = 23; alum n = 22 animals) before and one week after the last immunization. c. 
Frequency of vaccine-induced (post – pre) α4β7+ or d. CXCR3 PBs e. Frequency of vaccine-induced α4β7+ PBs in 
the blood of 17 humans enrolled in the RV132 and RV135 HIV-vaccine trials. Blood was collected before and at 14 
d from last vaccination (Wilcoxon signed–rank test). 
 
The relevance of these findings in humans was tested by measuring the frequency of 
vaccine-induced α4β7+ and CXCR3+ PBs in the blood of vaccinees enrolled in the RV135 
and RV132 trials, which used an ALVAC (vCP1521)–HIV + rgp120 (MN/A244) that was 
adjuvanted either with alum or MF59, respectively [83]. We observed similar differences, 
consistent with the macaque results, in α4β7 levels on circulating PBs in immunized humans 
(Fig.9e). 
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NATURAL KILLER CELLS   
The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. 
RV144 secondary immune correlate analysis demonstrated that the combination of low 
plasma anti-HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular 
cytotoxicity (ADCC) inversely correlate with infection risk. One hypothesis is that the 
observed protection in RV144 is partially due to ADCC-mediating antibodies [89]. One of 
the function of Natural Killer cells (NK-cells) to mediate ADCC. CD16 (FcγRIII) expressed 
on their cellulare membrane recognize and bind to the Fc portion of the antibody bounded 
on the surface of a pathogen-infected target cell. Once the link between NK and infected 
cells, through the antibody, happen, NK-cells start to release cytotoxic cytokines [90]. For 
this reason mucosal (NK) cells that express NKG2A and NKp44 [85, 86] receptors were 
studied in the two groups of animals. Rectal biopsies were analyzed at one week after the 
last immunization for the frequency and function of NK cells by flow cytometry (Fig. 10).  
 
 
Fig. 10 | Representative flow cytometric plots defining ILCs (Innate Lymphoid Cells) in the rectal mucosa of rhesus 
macaques. ILCs were identified using a side-scatter versus forward-scatter gate and phenotypically defined as 
CD3−CD20− and NKG2A+ or NKp44+ cells, or as NKG2A−NKp44−cells. Purple line defines the gates used to 
calculate CD20−CD3− cells and NKp44+NKG2A+ cells. 
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Vaccination with both adjuvants increased the frequency of mucosal NKp44+ cells, and 
decreased that of NKp44−NKG2A− cells, as compared to the unvaccinated controls (Fig. 
11a, 11b). The stimulation of mucosal mononuclear cells with overlapping peptides that 
encompass the entire SIVmac251 gp120 proteome revealed a higher proportion of NKp44+IL-
17-producing cells in the alum group relative to MF59 recipients (Fig. 11c). Among the 
features associated with acquisition in this group of cells IL-17+ NK cells (% Env NKp44+IL-
17+) were associated with a reduced risk of acquisition in the multivariate analysis (R = 
0.377; data not shown). 
 
Fig. 11 | Adjuvant associated differences in NK subtype in rectal mucosa. Relative frequency of NKp44+ b. and 
NKp44- NKG2A-. c. Frequency of NKp44+ cells producing IL-17 after Env-stimulation (alum, n = 24; MF59, n = 22). 
 
PATIENT CHARACTERISTICS  
The characteristics of the participants belonging to the different groups are shown in Table 
2. The mean age was 43.3 years. The majority of patients were male (88%). Baseline CD4+ 
T-cell counts were not different between pre-ART CHI and LTNP. Significantly different were 
the copies of RNA-HIV in the plasma at the Setpoint and at the enrollment between the two 
groups.  
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Table 2 | Characteristics of study population 
 
IMMUNE CORRELATES OF CONTROL 
The importance of the antibodies against the V2 of gp120 in plasma and tissue has been 
underlined by many studies in humans and macaques in which HIV/SIV infection was 
prevented with a vaccine or controlled after ART interruption [43, 73, 91, 92].  We enrolled 
14 LTNP and 12 Pre-ART CHI patients mainly clade B (85%) and we characterized the V2 
response in plasma. First we studied the plasma reactivity against V2 of HIV gp120 linear 
overlapping 15-mers peptides of MN (clade B) isolate (Fig. 12a). Only 1 out of 12 CHI patient 
showed a low response against peptide 24 (Fig. 12b) . 4 out of the 14 LTNP showed a 
stronger wider response against the MN V2 gp120 regions (Fig.12c) 
Characteristic mean (range) CHI (n=12) LTNPs (n=14) 
Age 38.1 (22-64) 47.7 (39-57) 
Male Gender 100% 78.50% 
YY since diagnosis 2.03 (0.9-2.9) 21.3 (9.9 - 31.9) 
HIV-RNA copies at Setpoint (RNA copies/ml) 
657,019 (21,290-
4.000,000) 
1,615 (<37-
4,000) 
HIV-RNA copies  at the enrollment (RNA copies/ml) 
641,002 (14360 - 
4000000) 
1137 (<37-
4,751) 
CD4 count at Nadir (cells/ul) 366 (55-666) 517 (249-1,001) 
CD4 count at enrollment (cells/ul) 399 (55-929) 743 (289-2,177) 
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Fig. 12 | a. MN clade B V2 gp120 overlapping 15-mer peptides b. response of pre-ART CHI patients plasma to MN 
clade B V2 gp120 overlapping 15-mer peptides (n=12) c. response of LTNPs plasma to MN clade B V2 gp120 
overlapping 15-mer peptides (n=14) 
 
We then investigated the role of the conformation of the V2 of clade B (MN and Case A). 
We tested the plasma of the LTNPs and the pre-ART CHI patients with cyclic V2 (cV2) of 
gp120 isolated from MN (clade B). Although the levels of reaction to the linear peptides were 
higher in the LTNPs compared to the pre-ART CHI patients, the response was not 
significantly higher. The Plasma Enhance (RU) to cV2 of MN (clade B) (RU) of the LTNPs 
was significantly higher compared to that of the pre-ART CHI patients (P = 0.0012) (Fig. 
13a). Interestingly the reactivity of the LTNPs was higher also against other isolate cV2 of 
the same clade (Case A) and other clades (clade AE, Th023) (respectively P = 0.05 and P 
< 0.0001) but not against the isolate 1086 of clade C (Fig. 13b, 13c, 13d).  
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Fig. 13 | Response of LTNPs (green n=13) and pre – ART CHI patients (red n=12) against cV2 of a. MN clade B b. 
Case A clade B c. Th023 clade AE d. 1086 clade C 
 
Even more interestingly, the plasma reactivity to cV2 against the clade B isolates of all the 
patients (85% clade B) was inversely correlated with the viral load measured at the same 
time point (P =0.0021 and P =0.0136 for the two clade B isolates) (Fig. 14a, 14b).  
 
 
Fig. 13 | Correlation between plasma reactivity to cV2 of the two clade B isolates and the viral load in the plasma 
measured at the same time.  a. MN clade B b. Case A clade B  
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DISCUSSION 
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In this study, a prime-boost ALVAC/SIV-gp120/Alum vaccine strategy was used to immunize 
a group of Indian rhesus macaques. The aim of this study was to recapitulate the results of 
the HIV vaccine phase III clinical trial RV144, also known as Thai Trial, conducted in 
Thailand. In the RV144, ALVAC/HIV-gp120/Alum was administer on 16,000 volunteers and 
the regimen achieved moderate protection. We designed this study in order to re-test the 
vaccine efficacy and investigate the immune correlates of protection in rhesus macaques. 
In November 2016, in South Africa, started the phase III clinical trial HVTN 702. In this 
regimen the immunogens and schedule of the RV144 vaccine regimen have been adjusted 
in order to: increase the immunogenicity, match the circulating HIV clade in South Africa 
(clade C), and to achieve a durative protection. Very importantly, the gp120 boost, in HVTN 
702, is combined with MF59 instead of Alum. Our macaque study was also designed in 
order to explore the potential efficacy of MF59 by immunizing a second group of animals 
with ALVAC-gp120/MF59. In our study, ALVAC-gp120 vaccine regimen adjuvanted in alum 
resulted in a significant level of protection (44% at each challenge) in Indian rhesus 
macaques challenged intrarectally with low doses of SIVmac251, thus recapitulating the results 
of RV-144 clinical trial conducted in humans. Consistently, the animal model used in this 
study is predictive of the results observed in humans. On the contrary, the MF59-adjuvanted 
vaccine regimen did not protect from SIV acquisition upon rectal exposure of low doses of 
SIVmac251. However, MF59 was demonstrated to be highly immunogenic, because of its 
capability of eliciting higher antibody titers against gp120 protein as compared to alum. 
Nevertheless, the immunoglobulin titer against cyclic V2 peptide of gp120 in rectal mucosa 
was higher in the alum-adjuvanted group of animals. In the RV144 trial, the estimated 
efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 
31.2%. In the RV144, the IgG antibody binding to scaffolded V1V2 Env were associated with 
protection [43, 44]. We recapitulate this immune correlate of protection in macaques: in the 
Alum group in fact, the mucosal cV2 IgG response was associated with a decreased risk of 
SIV acquisition (log–rank test, P = 0.0018).  Since these antibodies were found in the rectal 
mucosa and were associated with antibody-dependent cell-mediated cytotoxicity activity 
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(ADCC)  in RV144 trial, we study the homing markers on plasma-cells precursors, PBs and 
we characterized NK-cells in the rectal mucosa that potentially can mediate ADCC.  PBs 
directed towards the gut mucosa were identified by the expression of α4β7 integrin on their 
surface, whereas PBs migrating to inflammatory sites were characterized according to their 
expression of CXCR3 chemokine receptor. Indeed, while α4β7 binds to MadCAM-1 and 
addresses cells to the gut mucosal layer, CXCR3 plays a major role in enabling the cells to 
target the inflammatory sites. Before immunization the frequency of blood circulating PBs 
from both groups of animals positively correlated with the expression of the α4β7 integrin 
(data not shown), indicating the higher the number of PBs, the higher the expression of 
α4β7. These findings suggest that PBs trafficking is regulated according to a homeostatic 
pattern, whereby under basal condition (i.e., without immunization) circulating PBs migrate 
towards the gut mucosa, which constitutes a portal of entry for the virus. In the alum-
adjuvanted group no significant alterations of the pattern of homing-marker expression were 
found after vaccination. On the contrary, the MF59-adjuvanted vaccine regimen resulted in 
a lower expression of α4β7 and a concurrent higher expression of CXCR3 on circulating 
PBs surface. Consistently, when vaccine-induced PBs were considered, the alum group 
showed a higher frequency of α4β7 than the MF59 group, and concurrently the MF59 group 
showed a significant increase in the expression of CXCR3. All these evidences appear to 
confirm that there is a natural homing homeostasis of blood circulating PBs, which is not 
altered by the ALVAC/SIV-gp120/Alum regimen and is profoundly affected by the 
ALVAC/SIV-gp120/MF59. Indeed, the MF59-adjuvanted vaccine seems to impair the traffic 
of PBs, skewing them to the inflammatory sites. Furthermore, in preliminary studies it was 
shown that MF59 adjuvant is a more potent immunogen and elicits a strong inflammatory 
response, diverting some subsets of immune cells towards the main sites of inflammation. 
In this scenario, the increase of CXCR3 and the decrease of α4β7 on circulating PBs plasma 
membranes strongly suggests that the MF59 may be able to alter the trafficking of PBs away 
from the gut mucosa where they are naturally headed to. Importantly, we observed and 
confirmed similar differences, consistent with the macaque results, in α4β7 levels on 
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circulating PBs in humans immunized in the RV135 and RV132 trials, which used an ALVAC 
(vCP1521)–HIV + rgp120 (MN/A244) that was adjuvanted either with alum10 or MF59, 
respectively. Next, we studied mucosal ILCs (Innate Lymphoid Cells) including natural killer 
(NK) cells that express NKG2A and NKp44 receptors. Within the mucosal ILC population, 
NKG2A+ cells mediate cytotoxicity, whereas NKp44+ cells produce IL-17, IL-22 and B cell–
activating factor (BAFF), thereby promoting epithelial integrity and mucosal homeostasis. 
NKp44−NKG2A− is a less-defined ILC population that produces cytokines, including IFN-γ. 
Vaccination with both adjuvants increased the frequency of mucosal NKp44+ cells, and 
decreased that of NKp44−NKG2A− cells, as compared to the unvaccinated controls. The 
stimulation of mucosal mononuclear cells with overlapping peptides that encompass the 
entire SIVmac251 gp120 proteome revealed a higher proportion of NKp44+IL-17-producing 
cells in the alum group relative to MF59 recipients. NKp44+IL-17-producing cells are ILCs 
that regulate mucosal integrity and that are functionally impaired in HIV infection. Correlative 
analysis in the alum group demonstrated associations between the risk of SIVmac251 
acquisition and the frequency of mucosal NKp44+IL-17+ as well as with the level of mucosal 
IgG to cyclic V2. Strikingly, within the MF59 group, the mucosal level of IgG to V2 was 
correlated with an increased risk of virus acquisition, which suggests that antibodies with 
seemingly similar specificities carry functional differences. The importance of the antibodies 
against the V2 region of gp120 in plasma and tissue has been underlined by studies in 
humans and macaques in which HIV infection was respectively prevented or controlled 
without ART [42, 73] .  This response has been associated with HIV prevention in human in 
the RV144 and confirmed through the results described in this study in macaque model. 
Furthermore, the V2 response has been identified recently as immune correlate of control 
in SIV-infected animals treated with monoclonal antibodies to α4β7 that achieved a 
sustained virological control after ART interruption [73]. Interestingly, only 30-50% of HIV 
patient (treated or non treated with ART) present low levels of V1V2 antibody response [93]. 
To date, sustained virological control without ART has not been achieved in human. Based 
on these observations we studied the V2 response in those HIV patients that naturally 
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control the course of HIV infection: the LTNPs. We studied a total of 26 patients belonging 
to two different groups: 12 pre-ART CHI patients and 14 LTNPs. We tested the plasma of 
the pre-ART CHI pantients and of the LTNPs to the overlapping peptides that encompass 
the entire V2 region of the gp120 protein of the MN clade B sequence and the cyclic form of 
the same antigen. We also tested the plasma of the patients to the cyclic form of cross-
clades HIV V2 gp120 antigens. Our data suggest that LTNPs have a significantly higher 
response to V2 of the gp120 homologous clade compared to the pre-ART CHI patients. 
Interestingly, this response reached statistical significativity also when measured to the V2 
of non-homologous clade (such as clade AE). Notably, this response was inversely 
correlated to the HIV plasma viral load. The functions of these antibodies and their relevance 
in controlling other HIV clades has to be explored in future studies. Overall our data underline 
the importance of the V2 region of the gp120 protein of HIV as a target for immunological 
pressure. Our data confirm the HIV vaccine efficacy achieved in human by the immunization 
with a prime/boost approach with an ALVAC-HIV + gp120-Alum vaccine (RV144, Thai Trial) 
in a SIVmac251 model.  In our study we demonstrated the importance of the antibodies to V2 
of the gp120 in prevention from SIV mucosal acquisition as demonstrated in the RV144 trial. 
We also found novel immune features (IL-17-producing NK-cells and PBs directed to 
mucosal site) that might have contribute in protection. We also confirmed part of these 
responses in humans vaccinated with an RV144-like regimen underlying the importance of 
animal models. The role of antibody to V2 region of SIV/HIV have been recently invigorated 
by their description in a rhesus macaque study in which substained virologic control was 
achived after ART suspension. We studied antibody to the V2 region of gp120 for the first 
time in a group of LTNPs comparing their quantity and their ability to bind cross clades 
antigens with the ones of HIV chronic infected individuals.  Plasma antibodies to V2 were 
stastistically higher in the LTNP group compared to the HIV chronic infected group. 
Interestingly, antibodies to V2 in the LTNP group were also able to bind cross clades 
antigens. Understanding the mechanism in which these antibody might contribute to mediate 
protection from HIV/SIV acqusition and HIV/SIV control will require further studies. Boost 
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the immune response in order to target V2 might increase the level of protection in future 
HIV/SIV vaccine studies and might contribute to achieve susbstained HIV control in HIV/SIV 
infected subjects.  
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